江苏康宁杰瑞生物制药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR 2024-04-10 08:40
Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights 2024-03-29 10:42
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033 2024-03-26 09:57
The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine 2024-03-22 18:42
Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024 2024-03-14 08:39
The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications 2024-02-07 09:50
Alphamab Oncology and 3DMedicines Entered into a Licensing Agreement with Glenmark for KN035 2024-01-25 10:40
First Patient Dosed in Phase Ⅲ Study of JSKN003 for the Treatment of Advanced HER2-Low Breast Cancer 2023-12-04 14:51
KN026 was Granted Breakthrough Therapy Designation by CDE 2023-11-07 08:51
Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO 2023-10-24 08:41
Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO 2023-10-24 08:41
Alphamab Oncology will update the research results of several core pipeline products at the 2023 ESMO Annual Meeting 2023-08-10 09:02
Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting 2023-06-06 09:06
IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE 2023-05-09 10:00
Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023 2023-04-17 14:01
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003 2023-03-16 09:58
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023 2023-03-15 10:06
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022 2022-12-12 15:51
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022 2022-12-12 15:00
Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022 2022-12-12 10:33
1 2 3 4